Compare · CRBP vs NVO
CRBP vs NVO
Side-by-side comparison of Corbus Pharmaceuticals Holdings Inc. (CRBP) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CRBP and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $204.84B, about 951.5x CRBP ($215.3M).
- Over the past year, CRBP is up 11.3% and NVO is down 17.5% - CRBP leads by 28.8 points.
- CRBP has been more active in the news (11 items in the past 4 weeks vs 10 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 10 for CRBP).
- Company
- Corbus Pharmaceuticals Holdings Inc.
- Novo Nordisk A/S
- Price
- $11.14-1.24%
- $46.26-1.97%
- Market cap
- $215.3M
- $204.84B
- 1M return
- +24.89%
- -10.31%
- 1Y return
- +11.29%
- -17.53%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 11
- 10
- Recent ratings
- 10
- 25
Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of novel therapeutics that target the endocannabinoid system in the fields of autoimmunity, fibrosis, and cancer. Its lead product candidate is lenabasum, a cannabinoid receptor type 2 (CB2) that is in Phase III clinical trial for the treatment of dermatomyositis; and in Phase II clinical trial to treat systemic lupus erythematosus. The company is also developing cannabinoid receptor type 1 inverse agonist program for treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; and CB2 agonist program for the treatment of cancer. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, which includes the Jenrin library of approximately 600 compounds and multiple issued and pending patent filings; and strategic collaboration with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of lenabasum in Japan. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest CRBP
- Chief Medical Officer Nicacio Leonardo Viana was granted 58,333 shares (SEC Form 4)
- Corbus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Chief Business Officer Saxena Nishant C bought $25,036 worth of shares (2,600 units at $9.63), increasing direct ownership by 3% to 77,900 units (SEC Form 4)
- Chief Executive Officer Cohen Yuval sold $171,396 worth of shares (17,000 units at $10.08) as part of a pre-agreed trading plan, decreasing direct ownership by 10% to 157,316 units (SEC Form 4)
- Chief Financial Officer Moran Sean F. sold $120,971 worth of shares (12,000 units at $10.08) as part of a pre-agreed trading plan, decreasing direct ownership by 12% to 84,694 units (SEC Form 4)
- SEC Form 424B5 filed by Corbus Pharmaceuticals Holdings Inc.
- SEC Form 10-Q filed by Corbus Pharmaceuticals Holdings Inc.
- Corbus Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update
- SEC Form 3 filed by new insider Nicacio Leonardo Viana
Latest NVO
- Novo Nordisk A/S downgraded by Deutsche Bank
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S